NASDAQ:TSRO

Tesaro Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$74.96
0.00 (0.00 %)
(As of 01/18/2019)
Add
Compare
Today's Range
$74.94
Now: $74.96
$74.97
50-Day Range N/A
52-Week Range
$23.41
Now: $74.96
$75.16
Volume1.19 million shs
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Tesaro logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$223.33 million
Book Value$4.58 per share

Profitability

Net Income$-496,120,000.00
Net Margins-295.67%

Miscellaneous

Market Cap$4.13 billion
Next Earnings DateN/A
OptionableOptionable

Headlines

Why Surface Oncology Stock Soared Today - Nasdaq
October 12, 2020 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

0.69 out of 5 stars

Medical Sector

1277th out of 2,019 stocks

Pharmaceutical Preparations Industry

564th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tesaro (NASDAQ:TSRO) Frequently Asked Questions

What stocks does MarketBeat like better than Tesaro?

Wall Street analysts have given Tesaro a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tesaro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Tesaro's earnings last quarter?

Tesaro, Inc. (NASDAQ:TSRO) issued its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing the consensus estimate of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to analyst estimates of $65.50 million. Tesaro had a negative net margin of 295.67% and a negative trailing twelve-month return on equity of 1,209.72%. Tesaro's quarterly revenue was up 94.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.82) earnings per share.
View Tesaro's earnings history
.

Who are Tesaro's key executives?

Tesaro's management team includes the following people:
  • Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)
  • Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)
  • Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)
  • Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)
  • Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43)

Who are some of Tesaro's key competitors?

What other stocks do shareholders of Tesaro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tesaro investors own include NVIDIA (NVDA), Clovis Oncology (CLVS), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Intercept Pharmaceuticals (ICPT), Incyte (INCY) and Regeneron Pharmaceuticals (REGN).

What is Tesaro's stock symbol?

Tesaro trades on the NASDAQ under the ticker symbol "TSRO."

What is Tesaro's stock price today?

One share of TSRO stock can currently be purchased for approximately $74.96.

How much money does Tesaro make?

Tesaro has a market capitalization of $4.13 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis.

What is Tesaro's official website?

The official website for Tesaro is www.tesarobio.com.

Where are Tesaro's headquarters?

Tesaro is headquartered at 1000 WINTER STREET, WALTHAM MA, 02451.

How can I contact Tesaro?

Tesaro's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.